Dianthus Therapeutics Inc. (DNTH)
NASDAQ: DNTHHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DNTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.75B
- EPS (TTM)
- -$4.21
- Dividend yield
- None
- 52-week range
- 32.22 – 117.88
- Day range
- 84.13 – 86.61
- Volume / Avg
- 562.47K / 825.33K
- Beta
- —
- Shares outstanding
- 55.93M
- Next earnings
- Nov 4, 2026
52-week range
DNTH stock today
Shares of Dianthus Therapeutics (DNTH) finished lower on Oct 7 at $84.88, a drop of 0.61% or $0.52 per share, versus the S&P 500's 0.22% decline. At this level, DNTH sits in the middle of its 52-week range of $32.22 to $117.88: 28.0% below the high, set on Aug 19, 2026 and 163.4% above the low. DNTH is up 106.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 144.6%.
Dianthus Therapeutics has posted a net loss over the last twelve months (EPS of -$4.21), so its P/E ratio is not meaningful. Dianthus Therapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Dianthus Therapeutics
Company profileDianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Marino Garcia M.B.A.
- Headquarters
- New York, NY
- Employees
- 92
- IPO year
- 2018
- Website
- dianthustx.com
Financial highlights
Full financialsIn fiscal 2025, Dianthus Therapeutics generated $2.0 million in revenue, down 67.3% from fiscal 2024, the first decline in the 10 years shown. Dianthus Therapeutics reported a net loss of $162.3 million, compared with a loss of $85.0 million a year earlier. Operating margin was -8739.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | — | — |
| Growth | -67.35% | +120.63% | — | — | — |
| Net income | $-162.34M | $-84.97M | $-43.55M | $-28.48M | $-71.14M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$140.80+65.88%
- Strong buy 1
- Buy 15
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-1.01
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-0.90 vs —
Dianthus Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs DNTH |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs DNTH |
| DNLIDenali Therapeutics Inc. | 19.16 | -0.62% | $3.06B | vs DNTH |
| MBXMBX Biosciences Inc. | 54.54 | -4.18% | $2.63B | vs DNTH |
| NAMSNewAmsterdam Pharma Company N.V. | 22.13 | -0.63% | $2.59B | vs DNTH |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs DNTH |
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs DNTH |
| URGNUroGen Pharma Ltd. | 40.70 | -1.76% | $1.99B | vs DNTH |
Indexes, lists and sector
Appears in lists
Dianthus Therapeutics stock FAQ
What is Dianthus Therapeutics's stock price today?
DNTH last traded at $84.88 as of Oct 7, 4:00 PM EDT, down 0.61% on the day. Prices are delayed at least 15 minutes.
When is Dianthus Therapeutics's next earnings date?
Dianthus Therapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-1.01.
Who is Dianthus Therapeutics's CEO?
Mr. Marino Garcia M.B.A. is the chief executive officer of Dianthus Therapeutics Inc., which has about 92 employees.
What is the DNTH 52-week high?
The 52-week high for DNTH is $117.88 and the 52-week low is $32.22. The stock is currently 28.0% below its high.